Otitis Media News and Research

RSS

Acute otitis media (AOM) is a common childhood disease with important ramifications to the overall health of infants and young children. The peak incidence of AOM occurs at 6 to 18 months of age, but it can also occur in older children. Complications of AOM include persistent middle ear effusion, chronic otitis media, transient hearing loss, or speech delays.

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

Clinical results of MedImmune's pivotal trial for motavizumab published

MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of Pediatrics.

30 Jan 2010

Pfizer provides update on Prevnar 13

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.

31 Dec 2009

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacteremia (bacteria in the blood).

22 Dec 2009

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

Immuno Laboratories, a leading provider of food and environmental allergy testing services, announced an agreement with Three Rivers Provider Network (TRPN), the largest and fastest growing proprietary Preferred Provider Organization (PPO) network in the United States.

18 Dec 2009

Pfizer's Prevenar 13 granted European marketing authorization

The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.

11 Dec 2009

FDA Advisory Committee votes in support of Pfizer's Prevnar 13

Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children.

19 Nov 2009

Treatment of allergic rhinitis can improve nasal and ocular symptoms

The treatment of allergic rhinitis is shown to improve co-existing conditions including conjunctivitis, asthma, sinusitis, otitis media with effusion (fluid in the middle ear) and sleep disorders according to an international expert at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

10 Nov 2009

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

MiddleBrook Pharmaceuticals, Inc. today announced its financial and operational results for the quarter ended Sept. 30, 2009.

5 Nov 2009

Complications of otitis media: Evolving trends in children

The introduction of pneumococcal vaccines for treating otitis media in children has not prevented complications from occurring, according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA. In fact, the research suggests that the focus has changed on what complications may arise.

8 Oct 2009

Study links improving air quality and fewer cases of cases of ear infections in children

Strides in improving the nation's air quality over the past ten years may be a factor in fewer cases of ear infections (otitis media) in children. These results are according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA.

8 Oct 2009

Medtronic receives global distribution rights for PEAK Surgical’s tissue dissection device

PEAK Surgical, Inc. and Medtronic, Inc. (NYSE: MDT) today announced an agreement that grants the Surgical Technologies business at Medtronic exclusive rights for global distribution and marketing of the PEAK PlasmaBlade® TnA (Tonsil and Adenoid) tissue dissection device for the ear, nose, and throat (ENT) market.

6 Oct 2009

Prompt diagnosis and treatment for otitis media benefits organ transplant recipients

Organ transplant recipients benefit significantly when they are monitored and receive prompt diagnosis and treatment for otitis media, a common inner ear infection.

5 Oct 2009

NIDCD awards research grant to Mobius Therapeutics

Mobius Therapeutics, LLC ™ has been awarded a research grant from the National Institute on Deafness and other Communication Disorders (NIDCD) to study its investigational procedure, selective Photodynamic Myringotomy (PDM).

25 Sep 2009

Severe plagiocephaly in babies can lead to ear infections

The recommendation to lay babies on their backs to sleep has reduced sudden infant death syndrome (SIDS), but has led to an increased number of infants with a skull deformity called deformational (or positional) plagiocephaly. Now new research suggests that infants with more severe plagiocephaly may have a higher rate of middle ear abnormalities associated with ear infections (otitis media), reports the September issue of The Journal of Craniofacial Surgery. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

25 Sep 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Intercell AG has announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.

8 Apr 2009

Wyeth's Prevenar vaccine for pneumococcal disease registered in Russia

Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year.

2 Mar 2009